APPLICATION OF ERITROPOETINS IN THE COMBINATION WITH INTRAVENOUS PREPARATIONS OF IRON AT CHEMIOINDUCED ANEMIA IN ONCOLOGY
https://doi.org/10.24060/2076-3093-2013-0-1-2-60-66
Abstract
The anemia being frequent complication of chemotherapy in oncology, considerably reduces quality and life expectancy of patients with malignant tumors. The international recommendations about application of eritropoez-stimulating agents are presented in article at chemioinduced anemia at oncological patients. Concepts of absolute and functional deficiency of iron are given. On the basis of the analysis of clinical researches application eritropoetins in a combination with intravenous preparations of iron is proved.
About the Author
L. N. Kudryashova
Bashkir State Medical University; Republican Clinical Oncological Dispancery
Russian Federation
Russian Federation
Oncology Chair with Courses of Oncology and Pathological Anatom, Ufa
References
1. Абрамов М.Е. Анемия на фоне химиотерапии. Пути коррекции / М.Е. Абрамов // Фарматека. -№8. – 2012. – С. 50-54.
2. Моисеев С.В. Железо карбоксимальтозат – новый внутривенный препарат для лечения железодефицитной анемии / С.В. Моисеев / /Клиническая фармакология и терапия. – 2012. № 21(2). – С. 2-7.
3. Новик А.В. Анемия и метаболические расстройства у онкологических больных / А.В. Новик // Практическая онкология. – 2009. Т.10. №3. – С. 131-139.
4. Павлов А.Д. Анемия при злокачественных новообразованиях: патогенез и лечение рекомбинантным человеческим эритропоэтином / А.Д.Павлов, Е.Ф. Морщакова, А.Г. Румянцев // Современная онкология. 2002. №4. – С. 50–54.
5. Птушкин В.В.Анемия в онкологии, подходы к лечению / В.В.Птушкин // Современная онкология. №1. – Т. 14. – 2012.– С. 14-18.
6. Aapro M., Osterborg A., Gasco P. et al. Prevalence and management of cancer related anaemia, iron deficiency and the specific role of i.v. iron // Ann. Oncol. – 2012. №10.
7. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapyrelated anemia: a multicenter, open-label, randomized trial // J ClinOncol. – 2004. – Vol. 22. – P. 1301–1307.
8. Auerbach M., Silberstein P., Webb R. et al. Darbepoietinalfa 500 mcg or 300 mcg once every three weeks with or without iron in patients with chemotherapy-induced anemia // Am J Hematol. – 2010. – Vol. 85(9). – P. 655–663.
9. Auerbach M., Ballard H., Glaspy J. et al. Clinical update: intravenous iron for anaemia // Lancet. – 2007. – Vol. 369. – P. 1502-1504.
10. Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia // J ClinOncol. – 2008. – Vol. 26(10). – P. 1611–1618.
11. Bohlius J., Wilson J., Seidenfeld J. et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients // J. Natl.Cancer Inst. 2006. –Vol. 98. – P. 708–714.
12. Caro J.J., Salas M., Ward A. et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review // Cancer. – 2001. – Vol.91. – №12. – P. 2214 – 2221.
13. Crawford J., Cella D., Cleeland C.S. et al. Relationship between Changes in Hemoglobin Level and Quality of Life During Chemotherapy in Anemic Cancer Patients Receiving Epoetin Alfa Therapy // Cancer. – 2002. – Vol. 95. – P. 888–895.
14. Dangsuwan P., Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy // Gynecol Oncol. – 2010. – Vol. 116(3). – P. 522–525.
15. Demetri G.D., Kris M., Wade J. et al. Quality of life benefit in chemotherapy patients treated with epoetinalfa is independent of disease response or tumour type: results from a prospective community oncology study // J ClinOncol. – 1998. – Vol. 16. – P. 3412-3425.
16. European Society for Medical Oncology ( ESMO). – Milan, 2010. С. 369– 374.
17. Gabrilove J.L., Cleeland C.S., Livingston R.B. et al. Clinical evaluation of once-weekly dosing of epoetinalfa in chemotherapy patients: improvement in haemoglobin and Quality of life are similar to threetimes-weekly dosing // J ClinOncol. – 2001. – Vol. 19. – P. 2875-2882.
18. Glaspy J., Crawford J., Vansteenkiste J. et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes // Br. J. Cancer. – 2010. – Vol. 102. – P. 1–315.
19. Glaspy J., Osterborg A., Ludwig H. et al. Evaluation of the association between (Hb) events and safety outcomes in cancer patients with chemotherapy induced anemia: an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials of darbepoetin // Eur J Cancer Suppl. – 2007. – Vol. 5. P.
20. Groopman J, Itri L. Chemotherapy-induced anemia in adults: incidence and treatment // J Nat Cancer Inst. – 1999. – Vol. 91. – P. 1616–1634.
21. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetinalfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. – Oncologist. – 2007. – Vol. 12. – Р. 231–242.
22. Khorana A., Francis C., Blumberg N. et al. Blood transfusions, thrombosis and mortality in hospitalized patients with cancer // Arch Intern Med. – 2008. – Vol. 168. –P. 2377–2381.
23. Littlewood T.J., Baretta E., Nortier J.W. et al. Effects of erythropoietin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomised, double-blind, placebo controlled trial // J Clin Oncol 2001. – Vol. 19. – P. 2865–2884.
24. Ludwig H., Van Belle S., Barrett-Lee P. et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients // Eur J Cancer. 2004. №40. – Р. 2293–2306.
25. Ludwig H., Muldur E., Endler G. et al. High prevalence of iron deficiency across different tumors correlates with anemia, increases during cancer treatment and is associated with poor performance status // Haematologica. – 2011. –Vol. 96. – P.
26. Moore R., Gaskell H., Rose P., Allan J. Metaanalysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data. BMC Blood Disord., 2011.
27. NCCN clinical practice guidelines. Cancer and chemotherapy-induced anemia. – 2010/ – Vol. 2: Available athttp://www.nccn.org/professionals/physician – gls/ PDF/anemia.pdf.
28. NCCN clinical practice guidelines. Cancer and chemotherapy-induced anemia. 2012. – Vol. 2. -Р.
29. Stasi R., Abriani L., Beccaglia P. et al. Cancerrelated fatigue: evolving concepts in evaluation and treatment // Cancer. – 2003. – Vol. 98. – P. 1786–1801.
30. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo controlled, randomized phase III trial of darbepoetinalfa in lung cancer patients receiving chemotherapy // J Natl Cancer Inst. – 2001. – Vol. 94. – P. 1211–1220.
31. Williamson L.M., Lowe S., Love E.M. et al. Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports // BMJ. – 1999. – Vol. 319. – P. 16–19.
Review
For citations:
Kudryashova L.N. APPLICATION OF ERITROPOETINS IN THE COMBINATION WITH INTRAVENOUS PREPARATIONS OF IRON AT CHEMIOINDUCED ANEMIA IN ONCOLOGY. Creative surgery and oncology. 2013;(1-2):60-66. (In Russ.) https://doi.org/10.24060/2076-3093-2013-0-1-2-60-66
Views:
673
Email this article 